The Human Variable 

Remission in ME/CFS is often described as spontaneous, yet nothing about it is random. The illusion of rarity comes from measurement bias. We record symptoms, not trajectory. When patient data is plotted longitudinally rather than episodically, a clear pattern emerges. Remission occurs when the body’s internal feedback systems, immune, autonomic, and metabolic, temporarily synchronize

By October 2025, CYNAERA’s federal-scale models identified between $1.05 trillion and $3.45 trillion in potential annual savings for the United States through modular frameworks that stabilize health, accelerate remission, and optimize budgetary flow across SSA, CMS, VA, and FEMA

Bioadaptive Systems Therapeutics™ (BST) is a new discipline of medicine that engineers remission by recalibrating fragile biological systems across immune, autonomic, mitochondrial, connective, hormonal, and environmental domains. Unlike traditional medicine, which classifies disease onset and treats within rigid silos, BST is phase-aware, terrain-first, and subtype-specific.

Introduction Myalgic encephalomyelitis/chronic fatigue syndrome is common, costly, and routinely missed until someone reads the chart as a timeline. Patients describe a delayed crash after effort that lasts days to weeks. CDC and NICE name this pattern post-exertional malaise and make it central to diagnosis (CDC, 2024; NICE NG206, 2021). Yet most people with ME/CFS still do not have a diagnosis, and many wait years for recognition, with the National Academies reporting both

Innovative Orthostatic Intolerance & POTS Detection for Faster Diagnosis. Orthostatic intolerance and POTS are increasingly more common, disabling, and often missed until someone reads the chart as a timeline. The signs of these conditions already lives in routine positions and vitals clinicians collect anyway: triage after upright waiting, first supine on the bed, a short bathroom walk and return, and discharge.

Developed through over 40 failed trial reconstructions of 20+ conditions, SPARC™ decodes clinical heterogeneity using patient-derived intelligence and CYNAERA’s AI-integrated logic stacks. Each failed trial costs between $20–40 million, and in rare or stigmatized conditions, these failures permanently deter further investment. Most failed trials didn’t fail because the drug was weak. They failed because the patient groups were misread.